SPERO THERAPEUTICS INC's ticker is SPRO and the CUSIP is 84833T103. A total of 89 filers reported holding SPERO THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $11,000 | -98.3% | 14,966 | -79.5% | 0.00% | – |
Q1 2022 | $636,000 | -47.0% | 73,070 | -2.6% | 0.00% | – |
Q4 2021 | $1,200,000 | -12.2% | 75,000 | +1.1% | 0.00% | – |
Q3 2021 | $1,366,000 | +46.9% | 74,207 | +11.4% | 0.00% | – |
Q2 2021 | $930,000 | -0.1% | 66,595 | +5.4% | 0.00% | – |
Q1 2021 | $931,000 | -31.3% | 63,172 | -9.6% | 0.00% | – |
Q4 2020 | $1,355,000 | +135.7% | 69,883 | +35.6% | 0.00% | – |
Q3 2020 | $575,000 | -14.9% | 51,526 | +3.2% | 0.00% | – |
Q2 2020 | $676,000 | +82.2% | 49,937 | +8.4% | 0.00% | – |
Q1 2020 | $371,000 | +2.2% | 46,064 | +21.9% | 0.00% | – |
Q4 2019 | $363,000 | -8.1% | 37,774 | +1.5% | 0.00% | – |
Q3 2019 | $395,000 | 0.0% | 37,223 | +8.6% | 0.00% | – |
Q2 2019 | $395,000 | -8.1% | 34,279 | +2.1% | 0.00% | – |
Q1 2019 | $430,000 | +90.3% | 33,571 | -8.6% | 0.00% | – |
Q4 2018 | $226,000 | -22.9% | 36,716 | +31.9% | 0.00% | – |
Q3 2018 | $293,000 | -19.3% | 27,828 | +12.7% | 0.00% | – |
Q2 2018 | $363,000 | +79.7% | 24,689 | +73.9% | 0.00% | – |
Q1 2018 | $202,000 | – | 14,199 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Atlas Venture Associates IX, LLC | 1,353,303 | $1,637,497 | 13.93% |
Anson Funds Management LP | 4,159,572 | $5,033,082 | 1.01% |
OUP Management Co., LLC | 249,070 | $301,375 | 0.68% |
Atlas Venture Life Science Advisors, LLC | 1,013,438 | $1,226,260 | 0.19% |
Murchinson Ltd. | 862,700 | $1,043,867 | 0.13% |
Alphabet Inc. | 889,979 | $1,076,874 | 0.07% |
AWM Investment Company, Inc. | 333,400 | $403,414 | 0.06% |
DAFNA Capital Management LLC | 125,000 | $151,250 | 0.05% |
Novo Holdings A/S | 468,902 | $567,371 | 0.04% |
XTX Topco Ltd | 58,368 | $70,625 | 0.01% |